Reviving Assets from Clinical Trial Setbacks
Each year, pharmaceutical companies face substantial losses from assets that fail in pivotal trials. DrugReboot.Ai is ThinkBio.Ai’s advanced platform designed to systematically analyze the root causes of clinical failure and identify alternative development paths. By combining proprietary data with AI-driven insights, it enables informed decision-making to recover and repurpose promising molecules.
From Sunk Costs to Strategic Recovery
DrugReboot.Ai performs root cause analysis to propose alternative strategies:
- Repurposing in a New Indication – Identifying alternative disease areas with stronger therapeutic potential
- Population Stratification – Pinpointing responsive patient cohorts
- Combination Therapy Design – Suggesting combinations with other targets to achieve superior therapeutic index.
Each recommendation is supported by evidence obtained through the BioThinkHub Knowledge Engine.
Integrated AI Framework for Rational
Repositioning
DrugReboot.Ai combines multimodal data, knowledge graphs and domain-specific foundation models to discover molecular features associated with drug response. It combines the molecular features with the patient’s clinical attributes to predict the reasons why the drug failed in the clinical trial. Additional analysis using disease models identifies strategies for salvaging the therapy. Delivered via secure cloud or on-premises deployment, the analysis provides actionable insights and supporting evidence to guide clinical and commercial decisions.
Key Features & Capabilities
Multimodal Data Fusion
Integrates clinical trial data, molecular profiles, biomarker signals, and patient stratification variables for a unified view of therapeutic performance.
Biomedical Knowledge Graphs
Leverages structured biomedical relationships to identify novel indications, mechanisms of action, and target-patient alignments
Foundation Model-Powered Insights
Applies fine-tuned large language and domain-specific models to uncover root causes of trial failure and generate repositioning hypotheses.
Indication Mapping & Patient Stratification
Identifies viable alternative indications and responsive subpopulations using real-world evidence and biological markers
Combination Therapy Discovery
Suggests rational co-therapies based on pathway analysis, drug interaction patterns, and therapeutic synergies
Actionable Repositioning Reports
Delivers expert-validated recommendations with supporting evidence, visualizations, and traceable rationale to accelerate decision-making
Secure & Flexible Deployment
Available as a secure cloud-based solution or deployable on-premises, ensuring compliance with enterprise data governance.
Resources
Contact Us
Would you like us to get in touch with you? Fill up the form & we will reach out to you
